DURECT Corporation Stock News

CUPERTINO, Calif. , Feb. 4, 2025 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that James E.

The article presents new trial data, including subgroup analyses and liver biomarkers, which have guided the design of the Company's planned Phase 3 trial CUPERTINO, Calif. , Jan. 28, 2025 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the publication of a peer-reviewed article on the AHFIRM trial data in NEJM Evidence.

CUPERTINO, Calif. , Nov. 25, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today announced the sale of its ALZET® line of osmotic pumps to Lafayette Instrument Co. (LIC), a portfolio company of Branf...

DURECT Corporation (NASDAQ:DRRX ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Jim Brown - Co-Founder, Chief Executive Officer, President, Director Tim Papp - Chief Financial Officer WeiQi Lin - Executive Vice President of Research and Development, Principal Scientist Conference Call Participants Thomas Yip - H.C. Wainwright Karl Burns - Northland Capital M...

-     Seeking to initiate Phase 3 registrational trial for larsucosterol with topline results expected within two years of initiation -     Webcast of Earnings Call Today, November 13 at 4:30 p.m. ET CUPERTINO, Calif.

CUPERTINO, Calif. , Nov. 6, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury, today announced that the company will report its third quarter financial results on Wednesday, November 13, 2024.

CUPERTINO, Calif. , Oct. 17, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today announce that it will deliver an oral and two poster presentations at The Liver Meeting 2024, organized by the America...

- Type B meeting with FDA held under Breakthrough Therapy designation resulted in agreement on key aspects of Phase 3 trial design - Single Phase 3 trial designed to enroll 200 U.S. patients with a 90-day survival primary endpoint; topline results expected within two years of trial initiation  - Protocol for Phase 3 trial builds on data from the AHFIRM Phase 2b trial; 30 mg and 90 mg doses of l...